Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Wilmington Pharmaceuticals
company
About
Wilmington Pharmaceuticals develops and licenses formulations for drug developments.
- 1 - 10
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $1.30M
- Industries
- Biotechnology,Health Care
- Founded date
- Jan 1, 2002
- Number Of Employee
- 1 - 10
- Operating Status
- Active
At Wilmington Pharmaceuticals, they develop and out-license patient-friendly, fast-dissolving formulations for established medicines. They achieve FDA approval and rapid commercialization for their licensing partners, minimizing regulatory risk while maximizing economic opportunity. Their points of differentiation provide you with an ideal development partner.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$1.30M
Wilmington Pharmaceuticals has raised a total of
$1.30M
in funding over 2 rounds. Their latest funding was raised on
Oct 26, 2006 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 26, 2006 | Series B | $1.30M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Wilmington Pharmaceuticals is funded by 2 investors.
Emergent Growth Fund
and Wilmington Investor Network
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Emergent Growth Fund
|
— | Series B |
Wilmington Investor Network
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
